Clinical Trials Sponsored by Clavis Pharma

Total 10410 results

MaaT Pharma

Recruiting

Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

Transplant Complication

Germany, France
Initiator Pharma

Not yet recruiting

Bioavailability Study to Compare Liquid vs Two Solid Formulations of IP2015

Bioavailability
Ellipses Pharma

Recruiting

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

Advanced Solid Tumor

United States, Spain, United Kingdom
Kibow Pharma

Recruiting

Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR2020-01 Study

Chronic Kidney Disease stage4

United States
Pherecydes Pharma

Recruiting

Phage Therapy in Prosthetic Joint Infection Due to Staphylococcus Aureus Treated With DAIR. (PhagoDAIRI)

Infection of Total Hip Joint Prosthesis | Infection of Total Knee Joint Prosthesis

France
Code Pharma

Recruiting

Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients With Moderate COVID-19

COVID-19

South Africa
Horus Pharma

Not yet recruiting

Evaluation of Neovis® Total Multi Versus Systane® Balance on Ocular Dryness Associated With Meibomian Gland Dysfunction

Dry Eye | Meibomian Gland Dysfunction
Initiator Pharma

Not yet recruiting

Study to Investigate the Pharmacodynamic Effects of IP2015 in Healthy Male Subjects Using the Intradermal Capsaicin Model

Pain
GNT Pharma

Recruiting

Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz (RODIN)

Ischemic Stroke

Korea, Republic of
Getz Pharma

Recruiting

Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver

Diabetes Mellitus, Type 2 | NAFLD | NASH - Nonalcoholic Steatohepatitis

Pakistan
Initiator Pharma

Not yet recruiting

A Phase II, Repeat Single Oral Dose Study of IPED2015 in Healthy Male Subjects With Erectile Dysfunction

Erectile Dysfunction
Kibow Pharma

Recruiting

Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV (CKD)

Chronic Kidney Disease stage4

United States
HRA Pharma

Recruiting

Observational Registry on Patients With Endogenous CS to Document Safety and Effectiveness of Ketoconazole. (KetoPASS)

Cushing Syndrome

Sweden, France, Croatia, Spain
Inventiva Pharma

Recruiting

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (NATiV3)

NASH - Nonalcoholic Steatohepatitis

United States, Argentina, Australia, Austria, Belgium, France, Germany, Israel, Portugal, Spain, United Kingdom, Canada, Italy, China, Brazil, Netherlands, Hungary, Bulgaria, Chile, Czechia, Mexico, Poland, Puerto Rico, South Africa, Uk...
MaaT Pharma

Recruiting

MaaT013 as Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients (ARES)

Acute Graft Versus Host Disease in Intestine | Steroid Refractory GVHD

Spain, France, Germany, Austria, Belgium, Italy
H.A.C. PHARMA

Recruiting

Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension

Neurogenic Orthostatic Hypotension

France
Scandinavia Pharma

Recruiting

CHACO Study: Control of Arterial Hypertension in Colombian Patients (CHACO)

Hypertension

Colombia
UCB Pharma

Completed

A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927

Epilepsy
Zealand Pharma

Active, not recruiting

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, United Kingdom, Germany, Israel
Longbio Pharma

Active, not recruiting

A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants

Chronic Spontaneous Urticaria

China
Lumos Pharma

Enrolling by invitation

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211) (OraGrowtH211)

Growth Hormone Deficiency

United States, Australia
LEO Pharma

Completed

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

Frontal Fibrosing Alopecia

United States
Amolyt Pharma

Completed

AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism

Chronic Hypoparathyroidism

Hungary, Netherlands
NervGen Pharma

Completed

A Phase I Safety Study of NVG-291 in Healthy Adults

Spinal Cord Injury

Australia
Nasus Pharma

Completed

Bioavailability of Nasal Epinephrine

Anaphylaxis

Israel
LEO Pharma

Completed

Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials (DELTA3)

Chronic Hand Eczema

Poland, Belgium, Canada, Denmark, Germany, Netherlands, Spain, France, Italy, United Kingdom
Tarsier Pharma

Completed

A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis

Non-infectious Anterior Uveitis

United States
Zealand Pharma

Completed

The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome (EASE SBS 4)

Short Bowel Syndrome

Denmark
NewAmsterdam Pharma

Active, not recruiting

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY)

Dyslipidemias | Hypercholesterolemia | Familial Hypercholesterolemia | Atherosclerotic Cardiovascular Disease | High Cholesterol

United States, Poland, Denmark, Czechia, China, Netherlands, Japan, Georgia
Tarsier Pharma

Completed

A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

Uveitic Glaucoma | Non-infectious Anterior Uveitis

United States, Germany, France
LEO Pharma

Completed

Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, Czechia, Germany, Poland, Spain, Australia, Japan
Ellipses Pharma

Completed

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

Ovarian Cancer

United States, United Kingdom, Hungary
Inventiva Pharma

Completed

Phase 2b Study in NASH to Assess IVA337 (NATIVE)

Non-Alcoholic Steatohepatitis (NASH)

United States, Spain, United Kingdom, France, Belgium, Austria, Switzerland, Australia, Germany, Slovenia, Bulgaria, Canada, Czechia, Italy, Mauritius, Poland
AM-Pharma

Terminated

(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI

Acute Kidney Injury Due to Sepsis

Belgium, Spain, United States, Austria, Denmark, France, United Kingdom, Finland, New Zealand, Australia, Germany, Canada, Netherlands, Ireland, Japan
LEO Pharma

Completed

Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7 (ECZTRA 7)

Atopic Dermatitis

Belgium, France, Germany, Poland, United Kingdom, Czechia, Spain
Zealand Pharma

Completed

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS) (EASE SBS 1)

Short Bowel Syndrome

United States, Denmark, Belgium, Germany, France, United Kingdom, Canada, Netherlands, Poland
Enyo Pharma

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

United States, Belgium, France, Puerto Rico, United Kingdom
Zealand Pharma

Completed

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, United Kingdom, Israel, Germany
LEO Pharma

Completed

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) (ECZTRA 2)

Atopic Dermatitis

United States, Denmark, United Kingdom, Korea, Republic of, Canada, Italy, Australia, Poland, Russian Federation
Zealand Pharma

Completed

A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM

Hypoglycemia | Diabetes Mellitus, Type 1

Canada
Zealand Pharma

Withdrawn

Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults

Glucose Metabolism Disorders | Hypoglycemia
Getz Pharma

Completed

Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus (RISE)

Type 2 Diabetes Treated With Insulin | Adverse Drug Event | Effect of Drug

Pakistan
LEO Pharma

Completed

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) (DELTA 2)

Chronic Hand Eczema

Belgium, Canada, Denmark, Germany, Netherlands, Poland, Spain
HRA Pharma

Completed

A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions (LIBRella)

Emergency Contraception

United States
LEO Pharma

Completed

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 1)

Chronic Hand Eczema

Canada, France, Germany, Italy, Poland, United Kingdom
ERYtech Pharma

Completed

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (Trybeca-1)

Pancreatic Adenocarcinoma

United States, United Kingdom, France
ERYtech Pharma

Terminated

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)

Triple Negative Breast Cancer

Spain, Belgium, Hungary
AlzeCure Pharma

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ACD856

Alzheimer Disease | Cognition Disorder

Sweden
AlzeCure Pharma

Completed

Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics

Alzheimer Disease | Cognition Disorder

Sweden
Getz Pharma

Completed

Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients (DQOL)

Quality of Life | Type 2 Diabetes | Metformin+Sitagliptin

Pakistan

3

Subscribe